Determination of the glycosylation-pattern of the middle ear mucosa in Guinea pigs.

Elisabeth Engleder, Elisabeth Demmerer, Xuang Wang, Clemens Honeder, Changjiang Zhu, Christian Studenik, Michael Wirth, Arnolder Christoph, Franz Gabor

    Veröffentlichungen: Beitrag in FachzeitschriftArtikelPeer Reviewed

    Abstract

    In the present study the glycosylation pattern of the middle ear mucosa (MEM) of guinea pigs, an approved model for middle ear research, was characterized with the purpose to identify bioadhesive ligands which might prolong the contact time of drug delivery systems with the middle ear mucosa (MEM). To assess the utility of five fluorescein labeled plant lectins with different carbohydrate specificities as bioadhesive ligands, viable MEM specimens were incubated at 4°C and the lectin binding capacities were calculated from the MEM-associated relative fluorescence intensities. Among all lectins under investigation, fluorescein-labeled wheat germ agglutinin (F-WGA) emerged as the highest bioadhesive lectin. In general, the accessibility of carbohydrate moieties of the MEM followed the order: sialic acid and N-acetyl-d-glucosamine (WGA) >> mannose and galactosamine (Lens culinaris agglutinin) > N-acetyl-d-glucosamine (Solanum tuberosum agglutinin) > fucose (Ulex europaeus isoagglutinin I) >> terminal mannose α-(1,3)-mannose (Galanthus nivalis agglutinin). Competitive inhibition studies with the corresponding carbohydrate revealed that F-WGA-binding was inhibited up to 90% confirming specificity of the F-WGA-MEM interaction. The cilia of the MEM were identified as F-WGA binding sites by fluorescence imaging as well as a z-stack of overlays of transmission, F-WGA- and nuclei-stained images of the MEM. Additionally, co-localisation experiments revealed that F-WGA bound to acidic mucopolysaccharides of the MEM. All in all, lectin-mediated bioadhesion to the MEM is proposed as a new concept for drug delivery to prolong the residence time of the drug in the tympanic cavity especially for successful therapy for difficult-to-treat diseases such as otitis media.

    OriginalspracheEnglisch
    Seiten (von - bis)124-130
    Seitenumfang7
    FachzeitschriftInternational Journal of Pharmaceutics
    Jahrgang484
    Ausgabenummer1-2
    DOIs
    PublikationsstatusVeröffentlicht - 30 Apr. 2015

    ÖFOS 2012

    • 301208 Pharmazeutische Technologie

    Zitationsweisen